Get the Stockscreener App
197.69
0.16%
0.31
Pre-market:
198.00
0.31
+0.16%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $197.69, with a volume of 6.29M.
It is up +0.16% in the last 24 hours and down -5.59% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$197.38
Open:
$198.67
24h Volume:
6.29M
Relative Volume:
0.90
Market Cap:
$349.67B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
83.72
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-3.62%
1M Performance:
-5.59%
6M Performance:
-13.12%
1Y Performance:
+2.78%
1-Day Range:
$196.44
$199.18
1-Week Range:
$196.23
$205.99
52-Week Range:
$176.57
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
197.69 | 349.12B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
874.00 | 775.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.79 | 542.44B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
186.68 | 290.80B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.50 | 275.14B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Long Term Gains - Yahoo Finance
Oncology innovation push leaves AbbVie stock muted amid sustained downside momentum - Traders Union
Upcoming Earnings Reports: AbbVie (ABBV), SoFi Technologies (SOF - GuruFocus
AbbVie Inc. stock (US00287Y1091): Why its immunology portfolio strength is suddenly worth a closer l - AD HOC NEWS
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Should You Buy AbbVie Stock Hand Over Fist Before April 29? - Yahoo Finance
AbbVie (ABBV) Reports Superior Efficacy of Rinvoq Over Humira in RA Study - GuruFocus
AbbVie (ABBV) Applies for New FDA Approval for Upadacitinib - GuruFocus
AbbVie Submits Application to FDA for Upadacitinib for Adults and Adolescents with Severe Alopecia Areata - Investing News Network
AbbVie Q1 Preview: Skyrizi, Rinvoq expected to drive growth recovery - Seeking Alpha
AbbVie Submits sNDA for Upadacitinib in Adults and Adolescents With Severe Alopecia Areata - Dermatology Times
Steady action for AbbVie stock as price holds near $197 support amid oversold reading - Traders Union
AbbVie stock edges lower as team shares new oncology research at AACR meeting - Traders Union
Kestrel Therapeutics Announces First Patient Dosed in the - GlobeNewswire
EvolveImmune receives $18M milestone from AbbVie partnership By Investing.com - Investing.com Canada
AbbVie submits application to FDA for Skyrizi for subcutaneous induction - TipRanks
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - CHEManager
AbbVie (ABBV) To Report Earnings Tomorrow: Here Is What To Expect - TradingView
AbbVie (ABBV) Maintains Dividend Strength as Core Drugs Drive Cash Flow - Insider Monkey
AbbVie's Planned $1B-Plus Research Triangle Campus Development Buoys Improved Life Sciences Outlook - Bisnow
SIIT Global Managed Volatility Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Submits Regulatory Application to FDA for SKYRIZI® Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease - Investing News Network
AbbVie (ABBV) Seeks FDA Approval for Skyrizi in Crohn's Disease Treatment - GuruFocus
AbbVie’s Q1 2026 Preview: Can Skyrizi and Rinvoq Sustain a $7B Quarterly Immunology Run Rate? - AlphaStreet
AB Sustainable Thematic Balanced Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie seeks FDA approval for Skyrizi subcutaneous induction By Investing.com - Investing.com Canada
AbbVie seeks FDA nod for SKYRIZI subcutaneous Crohn’s dosing By Investing.com - Investing.com Canada
AbbVie asks FDA to let Crohn's patients start SKYRIZI by shot - Stock Titan
Piper Sandler Cuts PT on AbbVie Inc. (ABBV) Ahead of Quarterly Results - Insider Monkey
AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE - Insider Monkey
AbbVie Inc. $ABBV Shares Acquired by Vanguard Group Inc. - MarketBeat
Sanctuary Advisors LLC Buys 6,911 Shares of AbbVie Inc. $ABBV - MarketBeat
Richard C. Young & CO. LTD. Acquires 6,966 Shares of AbbVie Inc. $ABBV - MarketBeat
Polaris Capital Management LLC Sells 22,167 Shares of AbbVie Inc. $ABBV - MarketBeat
Axecap Investments LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Advisors Capital Management LLC Purchases 20,147 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug - Yahoo Finance
Golden Reserve Retirement LLC Invests $1.68 Million in AbbVie Inc. $ABBV - MarketBeat
Calamos Advisors LLC Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Trading Down 1.1%Time to Sell? - MarketBeat
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026News and Statistics - IndexBox
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie Stock: Skyrizi and Rinvoq Already Cleared 2027 Guidance, But Does the Discount Still Make Sense? - TIKR.com
AbbVie’s move to revitalize Botox demand stymied by FDA questions - Crain's Chicago Business
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - Yahoo! Finance Canada
US FDA rejects AbbVie's wrinkle treatment due to manufacturing concerns - Reuters
Biopharma company AbbVie to create 730 jobs in Durham - WRAL
Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key Metrics - Yahoo Finance
Turtle Creek Wealth Advisors LLC Has $4.74 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Faces FDA Setback on TrenibotE Approval - GuruFocus
Quent Long Short Global Small Cap Fund LP Invests $2.17 Million in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):